WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$14.20 USD
+0.36 (2.60%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $14.00 -0.20 (-1.41%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.20 USD
+0.36 (2.60%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $14.00 -0.20 (-1.41%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Zacks News
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Wave Life Sciences (WVE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 34.53% Upside in Wave Life Sciences (WVE): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.5% in Wave Life Sciences (WVE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Wave Life Sciences (WVE) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Wave Life Sciences (WVE) have what it takes to be a top stock pick for momentum investors? Let's find out.
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
by Zacks Equity Research
Wave Life Sciences' stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase Ib/IIa study of WVE-006 for AATD.
Wave Life Sciences (WVE) Moves 74.1% Higher: Will This Strength Last?
by Zacks Equity Research
Wave Life Sciences (WVE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
How Much Upside is Left in Wave Life Sciences (WVE)? Wall Street Analysts Think 89.71%
by Zacks Equity Research
The mean of analysts' price targets for Wave Life Sciences (WVE) points to an 89.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
by Zacks Equity Research
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
WVE Stock Soars on Upbeat Efficacy Data From Muscle Disease Study
by Zacks Equity Research
Wave Life Sciences stock soars 53% on positive interim data from a mid-stage study showing superior efficacy of investigational DMD drug, WVE-N531.
Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -56.25% and 20.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 75.68% and 1.55%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 33.33% and 4.29%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of 37.50% and 173.49%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -550% and 72.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Wave Life Sciences (WVE) delivered earnings and revenue surprises of -11.90% and 47.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2seventy bio, Inc. (TSVT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 60.78% and 236.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Wave Life Sciences (WVE) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -23.26% in 4 Weeks, Here's Why the Trend Might Reverse for Wave Life Sciences (WVE)
by Zacks Equity Research
Wave Life Sciences (WVE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences
by Zacks Equity Research
AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.
All You Need to Know About Wave Life Sciences (WVE) Rating Upgrade to Buy
by Zacks Equity Research
Wave Life Sciences (WVE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
4 Drug Stocks That More Than Doubled This Year
by Zacks Equity Research
We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.
Wave Life Sciences (WVE) Up 26% on Collaboration With GSK
by Zacks Equity Research
Wave Lifesciences (WVE) signs a four-year research collaboration with GSK to advance discovery and development of oligonucleotide therapeutics focusing on novel genetic targets